Paricalcitol

Breastfeeding
  • TRADE NAME: Zemplar (AbbVie)
  • INDICATIONS: Secondary hyperparathyroidism associated with renal failure
  • CLASS: Vitamin D receptor agonist
  • HALF-LIFE: 4–7 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Bile acid sequestrants, Cardiac glycosides, Conivaptan, Danazol, Darunavir, Delavirdine, Digitalis (with overdose of paricalcitol), Digoxin, Ergocalciferol, Indinavir, Ketoconazole, Orlistat, Orlistat, Strong CYP3A4 inhibitors, Sucralfate, Telithromycin, Thiazide diuretics, Tocilizumab, Voriconazole

PREGNANCY CATEGORY: C

Contra-indicated in patients with evidence of vitamin D toxicity or hypercalcemia.

Our database has 76 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of paricalcitol in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 08/02/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top